TORIPALIMAB IN COMBINATION WITH CONCURRENT CHEMORADIATION IN PATIENTS WITH ADVANCED/METASTATIC ESOPHAGEAL CARCINOMA: PROTOCOL FOR A SINGLE-ARM, PROSPECTIVE, OPEN-LABEL, PHASE II CLINICAL TRIAL
第一作者机构：[1]Sichuan Cancer Hospital and Institute, Chengdu, China
推荐引用方式(GB/T 7714)：
Wu Lei,Wang Yi,Wan Gang,et al.TORIPALIMAB IN COMBINATION WITH CONCURRENT CHEMORADIATION IN PATIENTS WITH ADVANCED/METASTATIC ESOPHAGEAL CARCINOMA: PROTOCOL FOR A SINGLE-ARM, PROSPECTIVE, OPEN-LABEL, PHASE II CLINICAL TRIAL[J].JOURNAL FOR IMMUNOTHERAPY OF CANCER.2021,9:A444-A444.doi:10.1136/jitc-2021-SITC2021.413.
APA：
Wu, Lei,Wang, Yi,Wan, Gang,Lv, Jiahua,Wang, Qifeng...&Li, Tao.(2021).TORIPALIMAB IN COMBINATION WITH CONCURRENT CHEMORADIATION IN PATIENTS WITH ADVANCED/METASTATIC ESOPHAGEAL CARCINOMA: PROTOCOL FOR A SINGLE-ARM, PROSPECTIVE, OPEN-LABEL, PHASE II CLINICAL TRIAL.JOURNAL FOR IMMUNOTHERAPY OF CANCER,9,
MLA：
Wu, Lei,et al."TORIPALIMAB IN COMBINATION WITH CONCURRENT CHEMORADIATION IN PATIENTS WITH ADVANCED/METASTATIC ESOPHAGEAL CARCINOMA: PROTOCOL FOR A SINGLE-ARM, PROSPECTIVE, OPEN-LABEL, PHASE II CLINICAL TRIAL".JOURNAL FOR IMMUNOTHERAPY OF CANCER 9.(2021):A444-A444
医学